81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases von Gettinger, S.N, Bazhenova, L, Salgia, R, Langer, C.J, Gold, K.A, Rosell, R, Shaw, A.T, Weiss, G.J, Narasimhan, N.I, Dorer, D.J, Rivera, V.M, Clackson, T, Haluska, F.G, Camidge, D.R

Volltext

1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA von Gettinger, S., Bazhenova, L., Salgia, R., Langer, C., Gold, K., Rosell, R., Shaw, A., Weiss, G.J., Narasimhan, N.I., Dorer, D.J., Rivera, V.M., Clackson, T., Haluska, F.G., Camidge, R.

Volltext

A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies von Gettinger, S., Weiss, G.J., Salgia, R., Bazhenova, L., Narasimhan, N.I., Dorer, D.J., Rivera, V.M., Zhang, J., Clackson, T., Haluska, F., Shaw, A.T., Camidge, D.R.

Volltext